|
Born September 6, 1964, Saint-Raphael (France); Married, 3 children
|
Among Dr Escary’s major scientific achievements at Institut Pasteur (1988-96, Unité de Génétique Cellulaire directed by Nobel Prize Winner Pr François Jacob, Unité d’Embryologie Moléculaire directed by Dr Philippe Brûlet, Paris, France) the very first single & double knock out transgenic mouse models for cytokine genes worldwide, and the discovery of key physiological functions of cytokines in immune & nervous systems development and response to injury (Nature 363, 361-363, 1993; Neuron 11, 1175-1185, 1993; Curr Biol. 6, 686-694, 1996). Then the generation of first transgenic mice models of Hormone Sensitive Lipase at UCLA, a work sponsored by the pharmaceutical company GlaxoWellcome (Les Ulis, France). |
|
As head of the genome variability program (1998-99) at the French national genotyping center, he also completed with his team the first high density SNP map of the human chromosome 14 (Genomics 70, 153-164, 2000), and invented with Pr Beckmann (co director of CNG) an innovative multiplexing method for doing high throughput SNP discovery using denaturing-high performance liquid chromatography (D-HPLC) that enabled the discovery of novel pathogenic mutations not detected by sequencing (Human Mutation, 16, 518-526 (2000). |
Dr Escary is a member of the New York Academy of Sciences (NYAS), the American Chemical Society (ACS), and was an alumni of the Young Leaders Program (2005) of the French-American Foundation (NY, USA). |
|
Business Executive Advisor : Principle of Alchemy Biomedical Consulting, Cambridge, UK, has over 30 years experience in the pharmaceutical industry both in research and in senior executive roles. He served with 4 of the top 10 Pharma companies: Zeneca, Pfizer, Glaxo, and most recently with F. Hoffman La-Roche as Global Head of Drug Discovery, Roche Pharma. In this role he had responsibility for the output of clinical candidate drugs from approximately 2000 scientists across Roche’s 5 research sites. Dr Brown has extensive experience of pharmaceutical R&D in all phases from early discovery through clinical trials, and he has experience of leading research in all major disease areas. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and he led the team that developed Viagra through to proof of concept (clinical efficacy) in man. |
At Roche, Dr Brown also served on the committee responsible for clinical drug development and he was a core member of the Business Development Committee responsible for in-licensing of products and for technology agreements and acquisitions. Dr Brown received his PhD in Chemistry from the University of Bristol. He is an Editor-in-Chief of Current Opinion in Drug Discovery and Development, and is author of more than 50 primary and review publications and patents.
|
|
got his Ph.D. in molecular biology at the University of Paris 7. From 1987 to 1997, he developed new molecular tools for the study of plasmodium falciparum, at Pitié-Salpétrière Hospital in Paris, in the department of Professor Gentillini and in Pasteur Institute in department of biomedical parasitology of Dr Druilhe . After several months at the New York Medical Center, he joined the Pasteur Institute under the supervision of Dr Artur Scherf to study the genome variability of plasmodium falciparum and |
the survival process of the parasite in infected patients. |
|
Vice-President Strategic Planning :Jean-Marc Giry brings over 20 years of marketing and business development experience to GenOdyssee. He joins the company from X-PM Transition Partners, an Executive Interim and Transition Management Services company. Prior to this, Jean-Marc held the positions of Vice President, Strategic Marketing at Gemplus, the leading smart cards manufacturer, and of Director of Marketing for the French subsidiary of Oracle, the leading database and enterprise software vendor. In those positions, he developed a strong expertise in fields such as international management, |
business modelling and strategic planning, market positioning, and global communications of publicly traded companies. Jean-Marc received his MBA in enterprise management from H.E.C., the Jouy-en-Josas (France)-based business school in 1981, as well as a Master's Degree in Computer Sciences from Dauphine University (Paris, France) in 1982. |
|
got his Master of Science in International Management at the MBA Institute in Paris. He has 15 years experience in international financial management in publicly traded companies : Technomed (medical), Coflexip (oil services) and Vivendi (environment), including 3 years based in Germany and the U.K. Before joining GenOdysse, |
he was recruited by Vivendi to organize the finance and administration of its international water network activities. Prior to Vivendi, he held several senior financial positions including the financial control and management of Coflexip International. Bertrand Lellouche brings an extensive expertise in project management, financial control, human resources, administration and communication in an international environment. |
|
holds an MD from Internat des Hopitaux de Paris and a PhD in biochemistry. Dr Maral joins GenOdyssee from CHIRON Biopharmaceuticals Europe, where he had served as Director of Clinical and Scientific Affairs since 1995. While at Chiron, Dr Maral was responsible for the successful multinational organisation of clinical and preclinical development for several oncology, hematology and infectious disease products. |
Before joining CHIRON Biopharmaceuticals, Dr Maral served successively as Director of Clinical Research with PIERRE FABRE Laboratories, then Medical Director with Amgen France. Dr Maral will be in charge of developing the therapeutic protein variants discovered by GenOdyssee. |
|
Director, Protein Science:Thierry Menguy, Ph.D. got his Ph.D. in Enzymology, Structure and Engineering of proteins at the University of Paris Sud (Paris XI, Orsay). From September 1995 to August 2000, he worked at CEA (French Atomic Energy Commission) in the protein and membrane biophysics group headed by Prof Marc le Maire (CEN Saclay, France) where he acquired a strong experience in protein expression and purification, and the identification and characterization of soluble and membrane protein active sites. |
Thierry Menguy joined GenOdyssee in August 2000 where he brings an outstanding expertise in proteins and where he is in charge of high throughput production and purification and protein-protein interaction analysis of protein candidates for internal screening and pre-clinical studies. |
|
Senior Project Manager Pre clinical Development & Production : Yves Joulin, Pharm D, Ph.D. pharmacist, got its Ph.D. in neurosciences at the university of Paris XII. He has over 10 years of experience of product development in the pharmaceutical industry (neurological, inflammatory and cardiovascular products). Before joining Genodyssee, he was Head of Pharmacological Studies at Servier (1991-1994) in the area of cardiovascular, and then he joined Bioprojet, a company developing products in the areas of neurology, cardiology, and inflammation, as Director of Pre Clinical Development for 6 years. More recently, Yves Joulin was Senior Pre Clinical Project Manager, at Ferring Pharmaceuticals, a company developing cardiovascular and analgesic drugs. |
Yves Joulin joined GenOdyssee on January 2002 as Senior Project Manager. He is in charge of the pre clinical development and production of GenOdyssee's therapeutic protein variants. |
|
Pr Hervé Fridman: Cancer and Immunotherapy (Pharmacology & Clinical) U255 INSERM, Centre de Recherches Biomédicales des Cordeliers, 15 rue de l'Ecole de Médecine; Hôpital Georges Pompidou, Paris (France) |
|
Pr Michael Tovey: Infectious Diseases & Cancer (Pharmacology) Laboratory of Viral Oncology, UPR 9045 CNRS, Villejuif (France) |
|
Pr Fabien Zoulim : Hepatitis C (Pharmacology & Clinical) Laboratoire des Virus des Hépatites et Pathologies Associées, Unité 271 INSERM, Lyon (France) |
|
IFN alpha
Infectious diseases & cancer: Pr Michael Tovey
Laboratory of Viral Oncology, UPR 9045 CNRS, 94800 Villejuif (France).
Cancer and immunotherapy: Pr Hervé Fridman
U255 INSERM, Laboratoire " Immunologie Cellulaire et Clinique ", Centre de Recherches Biomédicales des Cordeliers, 15 rue de l'Ecole de Médecine, 75006 Paris (France).
Professor at Service d'immunologie, Hôpital Georges Pompidou (France).
|
Hepatology: Pr Stanislas Pol Hôpital Necker Enfants Malades, Service Gastro-Entérologie, 149 rue de Sèvres, 75015 Paris (France). EPO Hematology: Dr Nicole Casadevall Department of Hematology, Hôpital Hôtel Dieu, Paris (France). |
|
GenOdyssee proposes an innovative, low burn and efficient value creation model based on project management and outsourcing of its proprietary drug discovery process & production to highly skilled and experienced service provider companies. This low-burn model has proven successful and acceptable to industrial partners, then will be largely retained for development projects.
|
Founder, Chairman & Chief Executive Officer : Jean-Louis Escary 
Director, High Throughput Discovery Platform: Emmanuel Bottius
Vice-President Finance & Administration : Bertrand Lellouche
Vice-President Preclinical and Clinical Development:Jean Maral